FI119190B - Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi - Google Patents
Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi Download PDFInfo
- Publication number
- FI119190B FI119190B FI20065431A FI20065431A FI119190B FI 119190 B FI119190 B FI 119190B FI 20065431 A FI20065431 A FI 20065431A FI 20065431 A FI20065431 A FI 20065431A FI 119190 B FI119190 B FI 119190B
- Authority
- FI
- Finland
- Prior art keywords
- beta
- lactamase
- metallo
- protein
- sequence
- Prior art date
Links
- 102000006635 beta-lactamase Human genes 0.000 title claims description 45
- 108090000204 Dipeptidase 1 Proteins 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title description 12
- 230000008569 process Effects 0.000 title description 3
- 108060004734 metallo-beta-lactamase Proteins 0.000 claims description 103
- 102000020235 metallo-beta-lactamase Human genes 0.000 claims description 92
- 102000004190 Enzymes Human genes 0.000 claims description 47
- 108090000790 Enzymes Proteins 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 235000018102 proteins Nutrition 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 15
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000004481 post-translational protein modification Effects 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 7
- 229930186147 Cephalosporin Natural products 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 229940041011 carbapenems Drugs 0.000 claims description 6
- 229940124587 cephalosporin Drugs 0.000 claims description 6
- 150000001780 cephalosporins Chemical class 0.000 claims description 6
- 150000002960 penicillins Chemical class 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 5
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 5
- 241000194108 Bacillus licheniformis Species 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 2
- 240000001817 Cereus hexagonus Species 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 45
- 241000193755 Bacillus cereus Species 0.000 description 28
- 244000063299 Bacillus subtilis Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 150000003952 β-lactams Chemical class 0.000 description 15
- 108020004256 Beta-lactamase Proteins 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 101800001494 Protease 2A Proteins 0.000 description 12
- 101800001066 Protein 2A Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229940116108 lactase Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 5
- 229960002260 meropenem Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 101150079396 trpC2 gene Proteins 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003781 beta lactamase inhibitor Substances 0.000 description 4
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 101150015060 sigG gene Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000606124 Bacteroides fragilis Species 0.000 description 3
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 210000004913 chyme Anatomy 0.000 description 3
- 229960003324 clavulanic acid Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- -1 i.e. Proteins 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000013606 secretion vector Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 241001660259 Cereus <cactus> Species 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710150697 Inositol monophosphatase 1 Proteins 0.000 description 2
- 101710126181 Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000003460 beta-lactamyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010068385 carbapenemase Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000257169 Bacillus cereus ATCC 10987 Species 0.000 description 1
- 241000301512 Bacillus cereus ATCC 14579 Species 0.000 description 1
- 241000135056 Bacillus cereus G9241 Species 0.000 description 1
- 241001289971 Bacillus mycoides KBAB4 Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- TUPFOYXHAYOHIB-WZGOVNIISA-M sodium;(2s,5r,6r)-6-[[(2s)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]h Chemical compound [Na+].C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 TUPFOYXHAYOHIB-WZGOVNIISA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940020930 unasyn Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20065431A FI119190B (fi) | 2006-06-21 | 2006-06-21 | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| CNA200780023477XA CN101484577A (zh) | 2006-06-21 | 2007-06-19 | 经修饰的β-内酰胺酶及其制备方法 |
| US12/304,874 US7989192B2 (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| AU2007262916A AU2007262916B2 (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| KR1020097001283A KR101609243B1 (ko) | 2006-06-21 | 2007-06-19 | 변형 베타-락타마제 및 이의 제조 방법 |
| BRPI0713726-5A BRPI0713726B1 (pt) | 2006-06-21 | 2007-06-19 | Proteínas metalo-beta-lactamase modificadas, seu uso, métodos para preparação das referidas proteínas e para a produção de uma preparação homogênea de enzima metalo-beta- lactamase, molécula de nucleotídeo, vetor de expressão e microrganismo transgênico |
| JP2009515904A JP5306191B2 (ja) | 2006-06-21 | 2007-06-19 | β‐ラクタマーゼ修飾体およびその調製方法 |
| EP07765926.6A EP2038411B1 (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| ES07765926.6T ES2452321T3 (es) | 2006-06-21 | 2007-06-19 | Beta-lactamasa modificada y método para su preparación |
| CA2659691A CA2659691C (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| NZ573696A NZ573696A (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| RU2009101795/10A RU2009101795A (ru) | 2006-06-21 | 2007-06-19 | Модифицированная бета-лактамаза и способ ее получения |
| PCT/FI2007/050372 WO2007147945A1 (en) | 2006-06-21 | 2007-06-19 | Modified beta-lactamase and method for its preparation |
| ZA200810460A ZA200810460B (en) | 2006-06-21 | 2008-12-10 | Modified beta-lactamase and method for its preparation |
| NO20090297A NO342006B1 (no) | 2006-06-21 | 2009-01-19 | Modifisert beta-laktamase og fremgangsmåte for fremstilling derav |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20065431 | 2006-06-21 | ||
| FI20065431A FI119190B (fi) | 2006-06-21 | 2006-06-21 | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20065431A0 FI20065431A0 (fi) | 2006-06-21 |
| FI20065431L FI20065431L (fi) | 2007-12-22 |
| FI119190B true FI119190B (fi) | 2008-08-29 |
Family
ID=36651526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20065431A FI119190B (fi) | 2006-06-21 | 2006-06-21 | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7989192B2 (xx) |
| EP (1) | EP2038411B1 (xx) |
| JP (1) | JP5306191B2 (xx) |
| KR (1) | KR101609243B1 (xx) |
| CN (1) | CN101484577A (xx) |
| AU (1) | AU2007262916B2 (xx) |
| BR (1) | BRPI0713726B1 (xx) |
| CA (1) | CA2659691C (xx) |
| ES (1) | ES2452321T3 (xx) |
| FI (1) | FI119190B (xx) |
| NO (1) | NO342006B1 (xx) |
| NZ (1) | NZ573696A (xx) |
| RU (1) | RU2009101795A (xx) |
| WO (1) | WO2007147945A1 (xx) |
| ZA (1) | ZA200810460B (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| BR112012032206A2 (pt) * | 2010-06-16 | 2016-10-04 | Abbvie Inc | comparações de amostras de proteínas |
| EP2689250A1 (en) | 2011-03-23 | 2014-01-29 | AbbVie Inc. | Methods and systems for the analysis of protein samples |
| JP6087341B2 (ja) * | 2011-04-21 | 2017-03-01 | ビオメリュー・インコーポレイテッド | セファロスポリンに対する耐性の少なくとも１つの機構を質量分析により検出する方法 |
| JP6685925B2 (ja) | 2014-04-17 | 2020-04-22 | シンセティック バイオロジクス，インコーポレイテッド | 治療用として改善された特性を有するβ−ラクタマーゼ |
| CA2958755C (en) | 2014-08-28 | 2023-02-28 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
| CA2962959C (en) | 2014-10-08 | 2023-04-04 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
| FR3027307B1 (fr) | 2014-10-16 | 2016-11-04 | Azurrx Sas | Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant |
| WO2016105498A1 (en) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| JP6810697B2 (ja) | 2015-02-23 | 2021-01-13 | シンセティック・バイオロジクス・インコーポレイテッド | 腸内マイクロバイオームの保護のために抗生物質と共に使用するカルバペネマーゼ |
| KR20170122776A (ko) | 2015-03-06 | 2017-11-06 | 신세틱 바이오로직스, 인코퍼레이티드 | 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약 |
| EP3420078B1 (en) * | 2016-02-23 | 2022-05-25 | Da Volterra | Beta-lactamase variants |
| US10988749B2 (en) | 2016-02-23 | 2021-04-27 | Da Volterra | Beta-lactamase variants |
| KR20210040395A (ko) | 2018-08-05 | 2021-04-13 | 다 볼떼라 | 이식편 대 숙주 질환의 치료를 위한 조성물 |
| JP2021534091A (ja) | 2018-08-05 | 2021-12-09 | ダ・ヴォルテッラ | 抗がん剤の有効性を改善する方法 |
| WO2020185861A1 (en) * | 2019-03-11 | 2020-09-17 | Regents Of The University Of Minnesota | Proteins and methods for disrupting bacterial communication |
| KR20220123542A (ko) * | 2019-12-30 | 2022-09-07 | (재)씨젠의료재단 | 카바페넴 항생제에 대한 내성을 가지는 병원성 균주의 직접 검출 방법 |
| EP4148136A1 (en) | 2021-09-08 | 2023-03-15 | Da Volterra | An engineered yeast cell for the delivery of antibiotic-inactivating enzymes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI920206A0 (fi) | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| FI112666B (fi) * | 2001-11-06 | 2003-12-31 | Ipsat Therapies Oy | Itiöimätön Bacillus subtilis, sen valmistus ja käyttö |
| FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
-
2006
- 2006-06-21 FI FI20065431A patent/FI119190B/fi not_active IP Right Cessation
-
2007
- 2007-06-19 JP JP2009515904A patent/JP5306191B2/ja active Active
- 2007-06-19 BR BRPI0713726-5A patent/BRPI0713726B1/pt active IP Right Grant
- 2007-06-19 AU AU2007262916A patent/AU2007262916B2/en not_active Ceased
- 2007-06-19 NZ NZ573696A patent/NZ573696A/en not_active IP Right Cessation
- 2007-06-19 KR KR1020097001283A patent/KR101609243B1/ko not_active Expired - Fee Related
- 2007-06-19 US US12/304,874 patent/US7989192B2/en active Active
- 2007-06-19 WO PCT/FI2007/050372 patent/WO2007147945A1/en not_active Ceased
- 2007-06-19 CN CNA200780023477XA patent/CN101484577A/zh active Pending
- 2007-06-19 CA CA2659691A patent/CA2659691C/en active Active
- 2007-06-19 ES ES07765926.6T patent/ES2452321T3/es active Active
- 2007-06-19 EP EP07765926.6A patent/EP2038411B1/en active Active
- 2007-06-19 RU RU2009101795/10A patent/RU2009101795A/ru not_active Application Discontinuation
-
2008
- 2008-12-10 ZA ZA200810460A patent/ZA200810460B/xx unknown
-
2009
- 2009-01-19 NO NO20090297A patent/NO342006B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI20065431L (fi) | 2007-12-22 |
| US20090181004A1 (en) | 2009-07-16 |
| NO20090297L (no) | 2009-01-19 |
| AU2007262916A1 (en) | 2007-12-27 |
| ZA200810460B (en) | 2009-12-30 |
| US7989192B2 (en) | 2011-08-02 |
| BRPI0713726A2 (pt) | 2012-10-30 |
| KR20090046787A (ko) | 2009-05-11 |
| CN101484577A (zh) | 2009-07-15 |
| JP5306191B2 (ja) | 2013-10-02 |
| WO2007147945A1 (en) | 2007-12-27 |
| BRPI0713726B1 (pt) | 2023-01-10 |
| CA2659691A1 (en) | 2007-12-27 |
| KR101609243B1 (ko) | 2016-04-05 |
| CA2659691C (en) | 2015-05-19 |
| EP2038411A4 (en) | 2010-04-07 |
| JP2009540814A (ja) | 2009-11-26 |
| NZ573696A (en) | 2011-09-30 |
| WO2007147945A8 (en) | 2009-07-30 |
| EP2038411B1 (en) | 2014-02-26 |
| NO342006B1 (no) | 2018-03-12 |
| EP2038411A1 (en) | 2009-03-25 |
| ES2452321T3 (es) | 2014-03-31 |
| RU2009101795A (ru) | 2010-07-27 |
| AU2007262916B2 (en) | 2013-12-05 |
| FI20065431A0 (fi) | 2006-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101609243B1 (ko) | 변형 베타-락타마제 및 이의 제조 방법 | |
| Poirel et al. | Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae | |
| Danel et al. | OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa | |
| Poirel et al. | OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid-and integron-located gene | |
| JP5827681B2 (ja) | 改変型β−ラクタマーゼ並びにそれに関する方法及び使用 | |
| Osano et al. | Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance | |
| Barnaud et al. | Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate | |
| Poirel et al. | Identification of the novel narrow-spectrum β-lactamase SCO-1 in Acinetobacter spp. from Argentina | |
| Péduzzi et al. | Characterization and amino acid sequence analysis of a new oxyimino cephalosporin-hydrolyzing class A β-lactamase from Serratia fonticola CUV | |
| Dabos et al. | LMB-1 producing Citrobacter freundii from Argentina, a novel player in the field of MBLs | |
| Dubois et al. | Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid-and integron-encoded OXA-30 β-lactamase | |
| Prinarakis et al. | Characterization of a novel SHV α-lactamase variant that resembles the SHV-5 enzyme | |
| Achour et al. | First detection of CTX-M-28 in a Tunisian hospital from a cefotaxime-resistant Klebsiella pneumoniae strain | |
| Chen et al. | Detection of plasmid-mediated IMP-1 metallo-β-lactamase and quinolone resistance determinants in an ertapenem-resistant Enterobacter cloacae isolate | |
| Mammeri et al. | Extended-spectrum cephalosporinases in Enterobacteriaceae | |
| Arlet et al. | Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins | |
| AU2015308897B2 (en) | E. coli-based production of beta-lactamase | |
| Cheng | Structural and functional studies of antibiotic resistance enzymes | |
| Claverie et al. | Characterization of the Naturally Occurring | |
| Courvalin et al. | Genetic and Biochemical Characterization | |
| Azibi et al. | Characterization and Nucleotide Sequence | |
| Li-rong et al. | Detection of plasmid-mediated IMP-1 metallo-β-lactamase and quinolone resistance determinants in an ertapenem-resistantEnterobacter cloacaeisolate | |
| Cephalosporins | Clinical Isolate Confers Resistance to | |
| Harriau et al. | Capnocytophaga ochracea | |
| Stephanazzi et al. | OXA-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119190 Country of ref document: FI |
|
| MM | Patent lapsed |